Format

Send to

Choose Destination

See 1 citation found using an alternative search:

J Clin Pharmacol. 2005 Dec;45(12):1368-72.

Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment.

Author information

1
Department of Clinical Pharmacology, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA.

Abstract

Eighteen adult subjects with mild to moderate hepatic impairment and 18 healthy control subjects were given a single 15-mg dose of sirolimus by oral solution. Mean whole-blood sirolimus weight-normalized oral-dose clearances (CL/F) were significantly decreased (P = .02) in subjects with mild to moderate hepatic impairment by -31.8% and -36.0%, respectively, compared with controls. There were no significant differences in mean sirolimus C(max) and t(max) values among groups. The observed decreases in CL/F may be relevant in renal transplant patients with mild to moderate hepatic impairment, based on the close similarity of sirolimus CL/F in controls and previously studied stable renal transplant patients receiving multiple-dose administration of sirolimus and cyclosporine. There was considerable overlap in the CL/F values of hepatic-impaired subjects and controls, suggesting that whole-blood sirolimus trough concentrations in renal transplant patients exhibiting mild to moderate hepatic impairment be initially monitored to assess the need for dose adjustments.

PMID:
16291711
DOI:
10.1177/0091270005281350
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center